Rescue medication: Clinical Trials

23 trials of Rescue medication, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting, 6 completed, 5 terminated, 1 not yet recruiting. 23 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 223Recruiting 10, Completed 6, Terminated 5, Not yet recruiting 1, Withdrawn 1
Phase 18Recruiting 6, Completed 1, Not yet recruiting 1

Follow Rescue medication: new trials by email Literature Review of Rescue medication trials Research Report on Rescue medication

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer
Phase 1 / Phase 2Not yet recruitingMerck Sharp & Dohme LLC2902026-12-142026-11-02
A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)
MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo - Pain Management
Phase 2RecruitingMerck Sharp & Dohme LLC3802026-11-022026-11-17
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC602026-03-272026-11-10
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
MK-3120, EV, Pembrolizumab - Bladder Cancer
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC552026-02-092026-10-02
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
MK-1084, Pembrolizumab, Cetuximab - Malignant Neoplasm
Phase 2RecruitingMerck Sharp & Dohme LLC1402025-12-192026-11-10
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC2982025-07-302026-11-13
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC3602025-07-032026-10-09
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
R-DXD, I-DXD, Docetaxel - Lung Neoplasm
Phase 2RecruitingMerck Sharp & Dohme LLC1442025-05-282026-11-13
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC6052025-04-152026-11-13
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Zilovertamab vedotin, Rituximab, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse
Phase 2RecruitingMerck Sharp & Dohme LLC5942025-04-112026-11-13
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer
Phase 1 / Phase 2CompletedMerck Sharp & Dohme LLC352024-12-202026-11-05
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC2202024-06-202026-10-29
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
Danirixin, Placebo, Rescue medication - Pulmonary Disease, Chronic Obstructive
Phase 2TerminatedGlaxoSmithKline192017-11-152021-03-29
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device - Pulmonary Disease, Chronic Obstructive
Phase 2TerminatedGlaxoSmithKline542017-10-162020-07-31
Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Danirixin, Danirixin matching placebo, Standard of care - Pulmonary Disease, Chronic Obstructive
Phase 2CompletedGlaxoSmithKline6142017-04-252020-10-28
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
Sirukumab, Placebo, Rescue medication - Asthma
Phase 2WithdrawnGlaxoSmithKline2016-09-232018-08-31
A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily - Asthma, Efficacy
Phase 2CompletedAstraZeneca542015-06-252018-02-15
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
MK-1602, Placebo, Rescue medication - Migraine
Phase 2CompletedAllergan1952012-08-012016-12-09
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
MK-1602, Placebo-matching MK-1602, Rescue medication - Migraine
Phase 2CompletedAllergan8342012-07-012019-01-08
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
Fosaprepitant dimeglumine, 5-HT3 RA, Dexamethasone - Nausea, Vomiting
Phase 2TerminatedMerck Sharp & Dohme LLC1112011-10-252018-08-27

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Pulmonary Disease, Chronic Obstructive (5)  ·  Asthma (2)  ·  Esophageal Squamous Cell Carcinoma (2)  ·  Migraine Disorders (2)  ·  Agnosia (1)  ·  Biliary Tract Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Disease Progression (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Nausea (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)

Sponsors

Merck Sharp & Dohme LLC (16)  ·  GlaxoSmithKline (4)  ·  Allergan (2)  ·  AstraZeneca (1)

Countries

United States (14)  ·  Spain (9)  ·  South Korea (8)  ·  Chile (7)  ·  United Kingdom (7)  ·  Germany (6)  ·  Italy (6)  ·  Canada (5)  ·  China (5)  ·  France (5)  ·  Israel (5)  ·  Netherlands (5)  ·  Poland (5)  ·  Taiwan (5)  ·  Turkey (Türkiye) (5)

Top investigators

Andrea Ludwig-Sengpiel, Dr. (1)  ·  Anne-Marie Kirsten, Dr. (1)  ·  Anneliese Linnhoff, Dr. med. (1)  ·  Christine Grigat, Dr. (1)  ·  Dirk Skowasch, Prof. (1)  ·  Jutta Beier, Dr. med. (1)  ·  Margret Jandl, Dr. (1)  ·  Oliver Kornmann, Dr. (1)  ·  Rainard Fuhr, Dr. med. (1)  ·  Tanya Kralimarkova, Dr. (1)  ·  Ulrike Westerhausen, Dr. (1)

Results publications

PMID 22702508, PMID 25695403, PMID 30777086, PMID 39982105

NIH funding

2025 (2), 2005 (1), 2008 (1), 2014 (1), 2016 (1), 2017 (1), 2023 (1)